FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2175453042> ?p ?o ?g. }

• W2175453042 endingPage "520" @default.
• W2175453042 startingPage "509" @default.
• W2175453042 abstract "The clinical benefit of eribulin versus capecitabine was evaluated using health-related quality of life (HRQoL) data from a phase 3 randomized trial in patients with pretreated advanced/metastatic breast cancer (ClinicalTrials.gov identifier: NCT00337103). The study population has been described previously (Kaufman et al. in J Clin Oncol 33:594–601, 2015). Eligible patients received eribulin (1.4 mg/m2 intravenously on days 1 and 8) or capecitabine (1.25 g/m2 orally twice daily on days 1–14) per 21-day cycles. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire-Core 30 questions (QLQ-C30) and breast module-23 questions (QLQ-BR23), administered at baseline through 24 months, until disease progression or other antitumor treatment initiation. Minimally important difference (MID) and time to symptom worsening (TSW) were investigated. 1062 (96.4 %) Patients completed the EORTC questionnaire at baseline; overall, compliance was ≥80 %. Patients receiving capecitabine versus eribulin had significantly worse symptoms (higher scores) for nausea/vomiting (MID 8; P < 0.05) and diarrhea (MID 7; P < 0.05). Treatment with eribulin versus capecitabine, led to worse systemic therapy side-effects (dry mouth, different tastes, irritated eyes, feeling ill, hot flushes, headaches, and hair loss; MID 10; P < 0.01). Clinically meaningful worsening was observed for future perspective (MID 10; P < 0.05) with capecitabine and for systemic therapy side-effects scale (MID 10; P < 0.01) with eribulin. Patients receiving capecitabine experienced more-rapid deterioration in body image (by 2.9 months) and future perspective (by 1.4 months; P < 0.05) compared with those on eribulin; the opposite was observed for systemic side-effects where patients receiving eribulin experienced more-rapid deterioration than those receiving capecitabine (by 2 months; P < 0.05). Eribulin and capecitabine were found to have similar impact on patient functioning with no overall difference in HRQoL. Patients receiving eribulin reported worse systemic side-effects of chemotherapy but reduced gastrointestinal toxicity compared with capecitabine." @default.
• W2175453042 created "2016-06-24" @default.
• W2175453042 creator A5010064853 @default.
• W2175453042 creator A5014192243 @default.
• W2175453042 creator A5031226414 @default.
• W2175453042 creator A5033987639 @default.
• W2175453042 creator A5041065594 @default.
• W2175453042 creator A5048804624 @default.
• W2175453042 creator A5064113568 @default.
• W2175453042 creator A5065306642 @default.
• W2175453042 creator A5079489429 @default.
• W2175453042 creator A5084322798 @default.
• W2175453042 date "2015-11-14" @default.
• W2175453042 modified "2023-10-18" @default.
• W2175453042 title "Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial" @default.
• W2175453042 cites W1848007259 @default.
• W2175453042 cites W1979316002 @default.
• W2175453042 cites W2026859784 @default.
• W2175453042 cites W2027926493 @default.
• W2175453042 cites W2033388957 @default.
• W2175453042 cites W2050104081 @default.
• W2175453042 cites W2073961237 @default.
• W2175453042 cites W2085772474 @default.
• W2175453042 cites W2093158866 @default.
• W2175453042 cites W2103607521 @default.
• W2175453042 cites W2112596743 @default.
• W2175453042 cites W2113464761 @default.
• W2175453042 cites W2115428190 @default.
• W2175453042 cites W2125060052 @default.
• W2175453042 cites W2127152525 @default.
• W2175453042 cites W2127557467 @default.
• W2175453042 cites W2130207808 @default.
• W2175453042 cites W2132771114 @default.
• W2175453042 cites W2135400278 @default.
• W2175453042 cites W2137545466 @default.
• W2175453042 cites W2139562398 @default.
• W2175453042 cites W2145821236 @default.
• W2175453042 cites W2150296977 @default.
• W2175453042 cites W2152035198 @default.
• W2175453042 cites W2154372913 @default.
• W2175453042 cites W2156635540 @default.
• W2175453042 cites W2167571044 @default.
• W2175453042 cites W2176579253 @default.
• W2175453042 cites W2189324492 @default.
• W2175453042 cites W2480680997 @default.
• W2175453042 cites W2992123728 @default.
• W2175453042 cites W4292024189 @default.
• W2175453042 doi "https://doi.org/10.1007/s10549-015-3633-7" @default.
• W2175453042 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4661183" @default.
• W2175453042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26567010" @default.
• W2175453042 hasPublicationYear "2015" @default.
• W2175453042 type Work @default.
• W2175453042 sameAs 2175453042 @default.
• W2175453042 citedByCount "41" @default.
• W2175453042 countsByYear W21754530422015 @default.
• W2175453042 countsByYear W21754530422016 @default.
• W2175453042 countsByYear W21754530422017 @default.
• W2175453042 countsByYear W21754530422018 @default.
• W2175453042 countsByYear W21754530422019 @default.
• W2175453042 countsByYear W21754530422020 @default.
• W2175453042 countsByYear W21754530422021 @default.
• W2175453042 countsByYear W21754530422022 @default.
• W2175453042 countsByYear W21754530422023 @default.
• W2175453042 crossrefType "journal-article" @default.
• W2175453042 hasAuthorship W2175453042A5010064853 @default.
• W2175453042 hasAuthorship W2175453042A5014192243 @default.
• W2175453042 hasAuthorship W2175453042A5031226414 @default.
• W2175453042 hasAuthorship W2175453042A5033987639 @default.
• W2175453042 hasAuthorship W2175453042A5041065594 @default.
• W2175453042 hasAuthorship W2175453042A5048804624 @default.
• W2175453042 hasAuthorship W2175453042A5064113568 @default.
• W2175453042 hasAuthorship W2175453042A5065306642 @default.
• W2175453042 hasAuthorship W2175453042A5079489429 @default.
• W2175453042 hasAuthorship W2175453042A5084322798 @default.
• W2175453042 hasBestOaLocation W21754530421 @default.
• W2175453042 hasConcept C121608353 @default.
• W2175453042 hasConcept C126322002 @default.
• W2175453042 hasConcept C141071460 @default.
• W2175453042 hasConcept C143998085 @default.
• W2175453042 hasConcept C159110408 @default.
• W2175453042 hasConcept C168563851 @default.
• W2175453042 hasConcept C2775930923 @default.
• W2175453042 hasConcept C2776387010 @default.
• W2175453042 hasConcept C2777909004 @default.
• W2175453042 hasConcept C2779951463 @default.
• W2175453042 hasConcept C2780580376 @default.
• W2175453042 hasConcept C526805850 @default.
• W2175453042 hasConcept C530470458 @default.
• W2175453042 hasConcept C71924100 @default.
• W2175453042 hasConceptScore W2175453042C121608353 @default.
• W2175453042 hasConceptScore W2175453042C126322002 @default.
• W2175453042 hasConceptScore W2175453042C141071460 @default.
• W2175453042 hasConceptScore W2175453042C143998085 @default.
• W2175453042 hasConceptScore W2175453042C159110408 @default.
• W2175453042 hasConceptScore W2175453042C168563851 @default.
• W2175453042 hasConceptScore W2175453042C2775930923 @default.
• W2175453042 hasConceptScore W2175453042C2776387010 @default.
• W2175453042 hasConceptScore W2175453042C2777909004 @default.

• next